MedTrace Logo

Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction

NCT00841438 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 786

Last updated 2010-05-04

No results posted yet for this study

Summary

The ADMIRAL (Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction) study demonstrated that early administration of abciximab in patients with ST elevation acute myocardial infarction prior to PCI improves clinical outcomes but no specifically designed randomized study has addressed the issue of early upstream use of GP IIb/IIIa inhibitors in ST elevation acute myocardial infarction who are undergoing PCI, especially in the era of routine pretreatment with 600 mg of clopidogrel. Therefore, the objective of the randomized ECLAT-STEMI study was to assess the hypothesis that the early upstream use of Clotinab is a useful therapy in patients with ST elevation MI undergoing PCI compared to "provisional use", even after pretreatment with a 600-mg loading dose of clopidogrel.

Conditions

Interventions

DRUG

Clotinab

Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg

DRUG

Clotinab

Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg

Sponsors & Collaborators

  • ISU ABXIS (Korea pharmaceutical company)

    collaborator UNKNOWN

  • Yonsei University

    lead OTHER

Principal Investigators

  • Yangsoo Jang, MD, Ph D · Division of Cardiology, Cardiovascular Hospital, Yonsei University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841438 on ClinicalTrials.gov